Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein
Abstract Background The F11R/JAM-A cell adhesion protein was examined as the therapeutic target in triple negative breast cancer (TNBC) with the use of the peptide antagonist to F11R/JAM-A, that previously inhibited the early stages of breast cancer metastasis in vitro. Methods The online in silico...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-08-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-023-03023-4 |
| _version_ | 1797451427508912128 |
|---|---|
| author | Radosław Bednarek Dagmara W. Wojkowska Marcin Braun Cezary Watala Moro O. Salifu Maria Swiatkowska Anna Babinska |
| author_facet | Radosław Bednarek Dagmara W. Wojkowska Marcin Braun Cezary Watala Moro O. Salifu Maria Swiatkowska Anna Babinska |
| author_sort | Radosław Bednarek |
| collection | DOAJ |
| description | Abstract Background The F11R/JAM-A cell adhesion protein was examined as the therapeutic target in triple negative breast cancer (TNBC) with the use of the peptide antagonist to F11R/JAM-A, that previously inhibited the early stages of breast cancer metastasis in vitro. Methods The online in silico analysis was performed by TNMPlot, UALCAN, and KM plotter. The in vitro experiments were performed to verify the effect of peptide 4D (P4D) on human endothelial cell lines EA.hy926 and HMEC-1 as well as on human TNBC cell line MDA-MB-231. The cell morphology upon P4D treatment was verified by light microscopy, while the cell functions were assessed by colony forming assay, MTT cell viability assay, BrdU cell proliferation assay, and Transepithelial/Endothelial Electrical Resistance measurements. The in vivo experiments on 4T1 murine breast cancer model were followed by histopathological analysis and a series of quantitative analyses of murine tissues. Results By in silico analysis we have found the elevated gene expression in breast cancer with particular emphasis on TNBC. The elevated F11R expression in TNBC was related with poorer survival prognosis. Peptide 4D has altered the morphology and increased the permeability of endothelial monolayers. The colony formation, viability, and proliferation of MDA-MB-231 cells were decreased. P4D inhibited the metastasis in 4T1 breast cancer murine model in a statistically significant manner that was demonstrated by the resampling bootstrap technique. Conclusions The P4D peptide antagonist to F11R/JAM-A is able to hinder the metastasis in TNBC. This assumption needs to be confirmed by additional 4T1 mouse model study performed on larger group size, before making the decision on human clinical trials. |
| first_indexed | 2024-03-09T14:54:30Z |
| format | Article |
| id | doaj.art-bbdd0686426b489e9d291f4e462a93e0 |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-03-09T14:54:30Z |
| publishDate | 2023-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-bbdd0686426b489e9d291f4e462a93e02023-11-26T14:18:30ZengBMCCancer Cell International1475-28672023-08-0123111910.1186/s12935-023-03023-4Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A proteinRadosław Bednarek0Dagmara W. Wojkowska1Marcin Braun2Cezary Watala3Moro O. Salifu4Maria Swiatkowska5Anna Babinska6Department of Cytobiology and Proteomics, Chair of Biomedical Sciences, Medical University of LodzDepartment of Haemostasis and Haemostatic Disorders, Medical University of LodzDepartment of Pathology, Chair of Oncology, Medical University of LodzDepartment of Haemostasis and Haemostatic Disorders, Medical University of LodzDepartment of Medicine, Downstate Medical Center, State University of New YorkDepartment of Cytobiology and Proteomics, Chair of Biomedical Sciences, Medical University of LodzDepartment of Medicine, Downstate Medical Center, State University of New YorkAbstract Background The F11R/JAM-A cell adhesion protein was examined as the therapeutic target in triple negative breast cancer (TNBC) with the use of the peptide antagonist to F11R/JAM-A, that previously inhibited the early stages of breast cancer metastasis in vitro. Methods The online in silico analysis was performed by TNMPlot, UALCAN, and KM plotter. The in vitro experiments were performed to verify the effect of peptide 4D (P4D) on human endothelial cell lines EA.hy926 and HMEC-1 as well as on human TNBC cell line MDA-MB-231. The cell morphology upon P4D treatment was verified by light microscopy, while the cell functions were assessed by colony forming assay, MTT cell viability assay, BrdU cell proliferation assay, and Transepithelial/Endothelial Electrical Resistance measurements. The in vivo experiments on 4T1 murine breast cancer model were followed by histopathological analysis and a series of quantitative analyses of murine tissues. Results By in silico analysis we have found the elevated gene expression in breast cancer with particular emphasis on TNBC. The elevated F11R expression in TNBC was related with poorer survival prognosis. Peptide 4D has altered the morphology and increased the permeability of endothelial monolayers. The colony formation, viability, and proliferation of MDA-MB-231 cells were decreased. P4D inhibited the metastasis in 4T1 breast cancer murine model in a statistically significant manner that was demonstrated by the resampling bootstrap technique. Conclusions The P4D peptide antagonist to F11R/JAM-A is able to hinder the metastasis in TNBC. This assumption needs to be confirmed by additional 4T1 mouse model study performed on larger group size, before making the decision on human clinical trials.https://doi.org/10.1186/s12935-023-03023-4Triple-negative breast cancerMetastasisEndothelial barrierEpithelial barrierTight junctionsMouse breast cancer model |
| spellingShingle | Radosław Bednarek Dagmara W. Wojkowska Marcin Braun Cezary Watala Moro O. Salifu Maria Swiatkowska Anna Babinska Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein Cancer Cell International Triple-negative breast cancer Metastasis Endothelial barrier Epithelial barrier Tight junctions Mouse breast cancer model |
| title | Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein |
| title_full | Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein |
| title_fullStr | Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein |
| title_full_unstemmed | Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein |
| title_short | Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein |
| title_sort | triple negative breast cancer metastasis is hindered by a peptide antagonist of f11r jam a protein |
| topic | Triple-negative breast cancer Metastasis Endothelial barrier Epithelial barrier Tight junctions Mouse breast cancer model |
| url | https://doi.org/10.1186/s12935-023-03023-4 |
| work_keys_str_mv | AT radosławbednarek triplenegativebreastcancermetastasisishinderedbyapeptideantagonistoff11rjamaprotein AT dagmarawwojkowska triplenegativebreastcancermetastasisishinderedbyapeptideantagonistoff11rjamaprotein AT marcinbraun triplenegativebreastcancermetastasisishinderedbyapeptideantagonistoff11rjamaprotein AT cezarywatala triplenegativebreastcancermetastasisishinderedbyapeptideantagonistoff11rjamaprotein AT moroosalifu triplenegativebreastcancermetastasisishinderedbyapeptideantagonistoff11rjamaprotein AT mariaswiatkowska triplenegativebreastcancermetastasisishinderedbyapeptideantagonistoff11rjamaprotein AT annababinska triplenegativebreastcancermetastasisishinderedbyapeptideantagonistoff11rjamaprotein |